Pancreatic Cancer UK Discovery and Translational Research Forum

Monday 13th & Tuesday 14th June 2022
The Oxford Martin School, University of Oxford,
34 Broad Street, Oxford OX1 3BD, UK

Dear Delegate,

Thank you very much for signing up to attend our Pancreatic Cancer UK Discovery and Translational Research Forum in Oxford on 13th & 14th June 2022.

As a reminder, the aim of the event is to:

- Gain a greater understanding of the work ongoing in labs carrying out basic discovery and translational research in pancreatic cancer across the UK
- Agree a shared understanding of strengths to build on and weakness to address
- Establish new contacts and potential collaborations
- Identify new research resources e.g. models, data sets, samples
- Build an improved sense of community in pancreatic cancer research
- Input into the ways that Pancreatic Cancer UK and other partners can strategically invest in the community over the next 5 years

We've put everything you'll need into this digital delegate pack:

- Have a read through the session programme
- Find out more about our speakers
- See all the venue details for the event and social

You can also read about our quick-fire presentations here.

Enjoy the event!

Best wishes,
Pancreatic Cancer UK

Get involved and use our official hashtag for the event: #OxfordPanCanForum

Please note, to reduce waste this is a digital delegate pack, there will not be a physical copy available on the day.

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland

Pancreatic Cancer UK

#OxfordPanCanForum

Programme

Monday 13th June 2022		
Time	**Session**	**Speakers**
11.00 – 11.15	**Welcome and introduction**	Dr Chris Macdonald, Head of Research, Pancreatic Cancer UK
11.15 – 13.00	**Cell of origin**	
11.15 – 11.30	Introduction	Prof. Axel Behrens, Scientific Director of the CRUK Convergence Science Centre, Institute of Cancer Research
11.30 – 12.00	Quick-fire presentations	Dr Sam Au, Imperial College London Curtis Rink, CRUK Beatson Institute Dr Beatriz Salvador, Cardiff University Haonan Xu, University of Oxford
12.00 – 13.00	Debate and discussion	Discussion led by Prof. Eric O'Neill, Professor of Cell and Molecular Biology, University of Oxford
13.00 – 14.00	**Lunch**	
14.00 – 15.45	**(epi)Genetics and subtypes**	
14.00 – 14.15	Introduction	Prof. David Chang, Professor of Surgical Oncology, University of Glasgow
14.15 – 14.45	Quick-fire presentations	Dr Rhiannon French, University of Oxford Dr Shalini Rao, University of Cambridge Dr Pinar Uysal-Onganer, University of Westminster
14.45 – 15.45	Debate and discussion	Discussion led by Dr Catherine Hogan, Lecturer, European Cancer Stem Cell Research Institute, Cardiff University
15.45 – 16.05	**Afternoon break**	
16.05 – 17.50	**Immunology**	
16.05 – 16.20	Introduction	Prof. Jen Morton, Professor of Pre-clinical models of pancreatic cancer, CRUK Beatson Institute
16.20 – 16.50	Quick-fire presentations	Dr Leo Carlin, CRUK Beatson Institute Dr Seth Coffelt, CRUK Beatson Institute Prof. Michael Dustin, Kennedy Institute of Rheumatology Dr Tim Halim, CRUK Cambridge Institute
16.50 – 17.50	Debate and discussion	Discussion led by Prof. Hemant Kocher, Professor of Liver and Pancreas Surgery, Barts Cancer Institute, Queen Mary, University of London
17.50 – 18.00	**Summary and close**	Dr Chris Macdonald, Head of Research, Pancreatic Cancer UK
18.15 – 22.00	**Evening social at the Cherwell Boathouse** Transport from The Oxford Martin School to the Boathouse will depart from 18.15	

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Programme

Tuesday 14th June 2022		
Time	**Session**	**Speakers**
09.30 – 09.40	**Welcome and introduction**	Dr Chris Macdonald, Head of Research, Pancreatic Cancer UK
09.40 – 11.25	**Stroma**	
09.40 – 09.55	Introduction	Dr Giulia Biffi, UKRI Future Leaders Fellow and Junior Group Leader, CRUK Cambridge Institute, University of Cambridge
09.55 – 10.25	Quick-fire presentations	Prof. Gerard Evan, The Francis Crick Institute Dr Andrea Mohr, University of Essex Mr John Moir, Freeman Hospital
10.25 – 11.25	Debate and discussion	Discussion led by Prof. Victoria Sanz-Moreno, Professor of Cancer Cell Biology, Barts Cancer Institute, Queen Mary University of London
11.25 – 11.45	**Mid-morning break**	
11.45 – 13.30	**Progression**	
11.45 – 12.00	Introduction	Prof. Michael C. Schmid, Chair of Cancer Biology, University of Liverpool
12.00 – 12.30	Quick-fire presentations	Dr Pilar Acedo-Nunez, University College London Dr Remi Samain, Barts Cancer Institute Dr Justin Sturge, University of Hull
12.30 – 13.30	Debate and discussion	Discussion led by Mr Keaton Jones, NIHR Academic Clinical Lecturer at Nuffield Department of Surgical Sciences, University of Oxford
13.30 – 13.45	**Summary, next steps and close**	Dr Chris Macdonald, Head of Research, Pancreatic Cancer UK
13.45 – 14.00	**Informal lunch** (packed lunches provided so you can take away)	

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Our Speakers

Dr Chris Macdonald
Head of Research, Pancreatic Cancer UK

Chris and his Team help support the UK research community to better detect, treat and care for people with pancreatic cancer. He works across the research community to understand the research challenges and priorities, define the charity's research strategies accordingly and deliver them effectively.

Prof. Axel Behrens
Scientific Director of the CRUK Convergence Science Centre, Institute of Cancer Research

Axel is the director of the convergence science centre, an innovative partnership between Imperial College, the Institute of Cancer Research, and Cancer Research UK with a mission to bring together engineering, physical sciences, life sciences and medicine to develop innovative ways to address challenges in cancer research to benefit cancer patients (https://www.convergencesciencecentre.ac.uk/).
He is also a senior team leader at the Institute of Cancer Research and full professor at Imperial College London (https://www.icr.ac.uk/our-research/researchers-and-teams/professor-axel-behrens), and Honorary Professor at London University College (KCL) and Sun-Yat-Sen University (Shenzhen, China).
He received his PhD degree in Molecular Genetics from Vienna University and completed his postdoctoral training in the University Hospital in Zurich (Switzerland). Axel's lab focuses on the biology of stem cells and their function in cancer.

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Prof. Eric O'Neill

Professor of Cell and Molecular Biology, University of Oxford

Eric is Professor of Cell and Molecular Biology at the Department of Oncology, University of Oxford. He leads the molecular oncology group and has a focused interest in early disease biology of pancreatic cancer and epigenetics, in particular how DNA 5mC/5hmC methylation deregulation leads to tumour progression. His work stems from foundation discovery of the Hippo signalling pathway in human cancer.

Prof. David Chang

Professor of Surgical Oncology, University of Glasgow

David is Professor of Surgical Oncology at University of Glasgow. His research focuses on the development and implementation of novel therapeutic strategies for pancreatic cancer particularly around DNA-damage response deficiency, by utilising molecular biomarkers of therapeutic response. David undertook his pancreatic surgical fellowship, PhD, and post-doctoral training in Australia. He was recruited to University of Glasgow in 2013, as part of an initiative to implement precision medicine in Scotland and the UK. He co-leads Precision-Panc, a Cancer Research UK precision medicine programme to deliver personalised cancer care for pancreatic cancer, and is the overall translational lead. He is also involved in the Precision Promise, a Pancreatic Cancer Action Network (USA) precision medicine initiative. He also contributes to ICGC-ARGO, aiming to shape the future of the next generation cancer genomic projects to ultimately realise the goals and promises of precision medicine.

Clinically David is a Consultant Pancreatic Surgeon at the West of Scotland Pancreatic Unit in Glasgow Royal Infirmary, a tertiary pancreatic referral centre for the West of Scotland. As a surgeon scientist, he aims to shorten the distance between the bench and the clinic to ensure meaningful and seamless translation.

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Dr Catherine Hogan

Lecturer, European Cancer Stem Cell Research Institute, Cardiff University

Catherine is Lecturer and Group Leader at the European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University. Her research focus is to unravel the cell biology of early pancreatic cancer with a view to improving early detection of disease. The Hogan lab recently discovered that healthy pancreas tissues use an evolutionarily conserved quality control system called cell competition to eliminate genetically mutant cells from tissues and prevent disease initiation. Current research is studying how KRAS mutant cells override cell elimination signals to remain in tissues and drive early tumorigenesis.

Prof. Jen Morton

Professor of Cancer Sciences, University of Glasgow Institute

Jen is a Senior Staff Scientist at the CRUK Beatson Institute and Professor at the University of Glasgow Institute of Cancer Sciences. She first started working on pancreatic cancer as a postdoc at the University of Massachusetts Medical School in 2004. Later she joined the Beatson Institute where she now leads the PRECISION-Panc Preclinical Laboratory. The lab's aim is to better understand pancreatic cancer and to identify and test new treatments targeting both tumor cells and stroma.

Prof. Hemant Kocher

Professor of Liver and Pancreas Surgery, Barts Cancer Institute, Queen Mary, University of London

Hemant is a surgeon-scientist. His clinical research interests include tissue banking, clinical trials, innovative surgical techniques, epidemiology, meta-analysis and patient care pathways. His translational research interests include pancreatic cancer stroma and tumour-stroma cross-talk including cell signalling, adhesion, metastasis, invasion leading to innovative therapies and novel biomarkers.

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Dr Giulia Biffi

UKRI Future Leaders Fellow and Junior Group Leader, CRUK Cambridge Institute, University of Cambridge

After completing her PhD at the University of Cambridge, CRUK Cambridge Institute, Giulia trained at Cold Spring Harbor Laboratory as an EMBO and HFSP Post-doctoral Fellow. Since 2020, she is a Junior Group Leader at the CRUK Cambridge Institute. She is also a UKRI Future Leaders Fellow and co-director of the Pancreatic Cancer Programme at the CRUK Cambridge Centre. Her laboratory focuses on understanding the tumour-promoting cross-talks between cancer cells and non-cancerous cells in pancreatic cancer to develop new treatments and diagnostics.

Prof. Victoria Sanz-Moreno

Professor of Cancer Cell Biology, Barts Cancer Institute, Queen Mary University of London

Victoria received her first degree in Chemistry and a Master's degree in Biochemistry from the University of Oviedo (Spain), followed by a PhD in chemical sciences from University of Cantabria. She did her postdoctoral studies at the ICR (London). In 2008, she received the Applied Biosystems and EACR 40th Anniversary Research Award. In 2011, she established her group with a CRUK Career Development Fellowship at King's College London. In 2017, she was awarded the BSCB Women in Cell Biology Early Career Medal and received a CRUK Senior Fellowship. In 2018, she was badged Werth Trust Fellow and was recruited as Professor of Cancer Cell Biology to Barts Cancer Institute (BCI-QMUL)- supported by Barts Charity. Victoria's lab works on understanding how Rho signalling and cytoskeletal dynamics control cancer cell growth and dissemination. Moreover, her lab is interested in deciphering how invasive cancer cells interact with their microenvironment while evading anti-cancer therapies.

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Prof. Michael C. Schmid

Chair of Cancer Biology, University of Liverpool

Michael is a research group leader and the Head of the Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK. He received his PhD from the University of Basel, Switzerland, and completed his postdoctoral training at the Moores Cancer Center, UCSD, USA. Michael's lab focuses on the complex biology of pancreatic cancer metastasis. Metastasis is the leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) frequently metastasises to the liver und liver metastasis is accompanied by the formation of an inflammatory-fibrotic metastatic microenvironment that supports the colonisation and outgrowth of disseminated cancer cells. The main goal of his team is to gain a better understanding of where, when and how host immune cells enhance or suppress metastatic progression in pancreatic cancer, with the ultimate aim of identifying new therapeutic possibilities to defeat pancreatic cancer.

Dr Keaton Jones

NIHR Academic Clinical Lecturer at Nuffield Department of Surgical Sciences, University of Oxford

Keaton is an NIHR Academic Clinical Lecturer in Hepato-Biliary and Pancreatic (HPB) surgery based in Oxford. He carries out his clinical work within the HPB department at the Churchill Hospital. He completed a DPhil in Oncology in 2018; investigating the role of tumour associated macrophages in the host response to radiation. His current work examines the therapeutic potential of macrophage reprogramming in the pancreatic tumour microenvironment. He is concurrently running a phase 1 clinical trial testing the safety of High Intensity Focused Ultrasound (HIFU) for the treatment of locally advanced and metastatic pancreatic cancer.

Pancreatic Cancer UK, Westminster Tower, 3 Albert Embankment, London SE1 7SP.
Registered charity number 1112708 (England and Wales), and SC046392 (Scotland)

Venue Details

Main conference venue

Oxford Martin School
University of Oxford
34 Broad Street
Oxford
OX1 3BD
Find it on google maps

The Oxford Martin School can be found on the corner of Holywell and Catte Street in central Oxford.

Monday evening social venue



The Cherwell Boathouse
Bardwell Road
Oxford
OX2 6ST
Find it on google maps

The bus from Oxford Martin School to the evening social venue will be departing from outside Oxford Martin School at 6.15pm on Monday.